ASSET OVERVIEW
A closer look at the opportunity.
Best-in-Class Potential Inhibitor
Highly selective oral KAT6A/6B inhibitor with superior preclinical anti-tumor activity and broader therapeutic window compared with Pfizer's PF-07248144.
Superior Selectivity & Potency
Stronger inhibitory activity, longer target residence time, and excellent selectivity profile with no meaningful off-target activity across 44 safety targets and 400 kinases.
Rapid Clinical Development Timeline
FDA IND cleared in April 2026 and China IND approved in May 2026, with Phase 1 monotherapy and combination studies initiating in 2026.
Clear Differentiation
Potential to overcome endocrine and fulvestrant resistance in HR+/HER2− breast cancer with strong rationale for combination use with SERDs and CDK4/6 inhibitors.
Large Market Opportunity
Targets the rapidly growing HR+/HER2− metastatic breast cancer market, including patients progressing after endocrine therapy and CDK4/6 inhibitors, representing a significant unmet need in precision oncology.
Source: existing JEA asset materials. These descriptions include historical development plans and sponsor-reported data; contact JEA for current status and supporting materials.
← Back to all opportunities